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The use of nanomaterials in the field of bone tissue engineering implants is continuously dealing with the development of 
innovative solutions to common problems, as infection by colonization with common microbial agents, antibiotic bacterial 
resistance, and the formation of new bone tissue. Among them, ZnO nanostructures are promising candidates thanks to 
their intrinsic antimicrobial activity and high biocompatibility.  
In this paper we aim to analyse the behaviour of ZnO nanocrystals (ZnO NCs), prepared with a new synthetic approach and 
not embedded in any composite matrix, for bone implants applications in-vitro. In particular, we have developed a novel, 
fast and reproducible microwave-assisted synthesis, obtaining highly-crystalline, round-shaped ZnO NCs of 20 nm in 
diameter as an extremely-stable colloidal solution in ethanol. Part of them were also chemically functionalized by 
anchoring amino-propyl groups to the ZnO surface (ZnO-NH2 NCs). Thus, the role of both ZnO NCs concentration and 
surface chemistry are tested in terms of biocompatibility towards pre-osteoblasts cells, promotion of cell proliferation and 
differentiation, and also in terms of antimicrobial activity against Gram positive and negative bacteria, such as Escherichia 
coli and Staphylococcus aureus, respectively. The results propose the ZnO-NH2 NCs as the most promising candidate to 
solve infections disease in bone implants and promote bone tissue proliferation at the same time, even at high 
concentrations. Whereas further investigations are needed for example to clarify the mechanism inhibiting biofilm 
formation and to investigate their role in in-vivo assays, we demonstrated that a fine and reproducible control over the 
chemical and structural parameters in ZnO nanomaterials can open new horizons in the use of functionalized ZnO NCs as a 
highly biocompatible and osteoinductive nanoantibiotic agent for bone tissue engineering.  
Introduction 
Nowadays, infections due to both Gram positive and negative 
pathogens are developing an evolved resistance to 
conventional antibiotics, impairing the effects of these drugs 
and posing serious problems to public health in the long term. 
Bone infections related to the implantation of orthopaedic 
implants are also facing this important antibiotic resistance 
issue. In particular, during the insertion of orthopaedic 
implants, bacteria from patient’s skin or mucosa can enter and 
adhere to the surface of implant and start to produce the 
antibiotic-resistant biofilm. This phenomenon results in 
osteomyelitis, localised bone destruction, prolonged 
hospitalisation, intense antibiotic treatment and, in the most 
serious cases, the replacement of the prosthesis.
1
 
It is thus necessary to start exploring either new antibiotic 
formulations or novel inhibition pathways to solve the 
bacterial resistance. Unfortunately, there is no certainty about 
the effectiveness of new antimicrobial drugs because bacteria 
can develop resistance in a timely manner. A new approach to 
overcome this challenging and infectious disease can be the 
use of antimicrobial nanomaterials. At first, nanomaterials 
were proposed as carriers for antibiotics to improve their 
pharmacokinetics and accumulation, and to reduce side effects 
.
2, 3
 A more innovative approach is the use of intrinsically-
antimicrobial nanomaterials, where the antimicrobial activity is 
not given by the pharmaceutical effect of an antibiotic, but it 
directly comes from the intrinsic properties of the nanosized 
material.
4
 To this end, several metal and metal oxide micro- 
and nanostructures have been proposed due to their ability to 
produce reactive oxygen species or dissolve in cations, both 
toxic for the majority of microbial cells.
5
  
Among them, zinc oxide (ZnO) is one of the most promising 
inorganic antimicrobial material. At the bulk or micro-sized 
level, it shows reduced toxicity to eukaryotic cells (it is actually 
considered a GRAS - generally recognized as safe - substance 
approved by FDA
6
) and can overcome the bacterial resistance 
to a certain extent.
5, 7
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The use of nanosized ZnO in biomedical applications,
8, 9
 in 
particular in bone tissue engineering, can be envisioned owing 
to its excellent antimicrobial properties, its biocompatibility 
and partial biodegradability,
10
 facile synthetic approaches in 
different sizes and shapes,
11
 and ease functionalization 
procedures of the surface.
12
 However, some issues are still 
unsolved concerning its potential toxicity to eukaryotic cells, 
which can impair at different dosages either healthy or tumor 
cells.
13, 14
 Thus, the use of ZnO as a nanoantibiotic
4
 requires a 
careful evaluation of the interactions between the 
nanomaterials and living cells, tissues and adjacent organs, and 
thus of dose administration and recalibration in the desired 
antimicrobial therapy.  
The antibacterial activity of ZnO nanostructures is related to 
three main probable mechanisms:
9
 (i) Reactive Oxygen Species 
(ROS) generation, (ii) release of Zn
2+
 cations and (iii) 
nanoparticle action. The ROS generation is the predominant 
mechanism and is promoted by the presence of crystalline 
defects in nano-sized ZnO structures, even in absence of any 
photoactivation stimulus. Due to the semiconductor band 
structure of ZnO, the electrons (e
-
) are promoted in the 
conduction band, whereas unpaired holes (h
+
) remain in the 
valence bands. The migration of both e
-
 and h
+ 
at the surface 
of the nanomaterials promotes their combination with water-
adsorbed molecules, generating ROS, thus hydroxyl radicals, 
singlet oxygen and superoxide radicals. Hydroxyl radicals are 
the most reactive species and they can quickly interact with 
every type of biological molecules.  
The release of Zn
2+
 ions from ZnO nanostructures, owing to 
their chemical instability in biological media,
10
 is another 
important mechanism in antibacterial activity of ZnO. Zn
2+
 ions 
can adsorb to the negatively charged bacteria surface through 
electrostatic forces. This interaction leads to the loss of the 
charge balance and deformations of the cell occur with 
consequent bacteriolysis. At the same time, Zn
2+
 can penetrate 
the cell membrane and interact with functional groups as 
sulphate and phosphate groups, resulting in a structural 
change of proteins and provoking the destruction of bacteria 
by unbalanced metabolism.  
Finally, the penetration of ZnO nanoparticles through the 
bacterial membrane and its consequent disorganisation also 
leads to bacterial death and thus is the third mechanism to 
take into account. This phenomenon is specifically due to the 
high specific area and surface energy of ZnO nanomaterials, 
able to adsorb and accumulate at the membrane and in the 
cytoplasm.  
Despite these most probable mechanisms against bacteria, the 
influence of the medium components, and the different sizes 
and surface chemistry of ZnO nanomaterials have also to be 
accounted. Therefore, the real antimicrobial mechanisms are 
still under investigation and have to be proven depending on 
ZnO morphology, chemical reactivity and surface, and bacteria 
cell type as well.
15
  
It is thus crucial to control the ZnO particles’ size, morphology 
and surface chemistry to efficiently tune on the one hand the 
antibacterial properties and on the other hand the 
biocompatibility towards healthy cells in case of biomedical 
implants or drug delivery devices.
16
 
Regarding specifically the use of ZnO nanomaterials for bone 
tissue engineering, ZnO was proposed as a suitable filler in 
composite matrices based on hydroxyapatite,
17, 18
 graphene 
oxide,
19
 polymers,
20, 21
 or as a coating for orthopaedic and 
dental implants promoting antibacterial response together 
with osteoblast growth, adhesion and their metabolic 
activity.
22
 Colon et al.
23
 have analysed the effects of ZnO 
micro- and nano-powders, pressed into compacts, on the 
osteoblast functions and S. epidermidis adhesion. The results 
of this study provided the first evidence of significantly greater 
osteoblast adhesion, alkaline phosphatase (ALP) activity, and 
calcium mineral deposition on nanophase ZnO with respect to 
the microphase counterpart, as well as a reduction of S. 
epidermidis adhesion. Moreover, it was reported that an 
appropriate concentration of zinc ions could enhance 
osteoblast cell proliferation and differentiation,
24
 promoting 
ALP activity and osteocalcin (OCN) secretion, which are 
considered an early marker and a major marker of osteoblast 
differentiation at the late stage, respectively.
25
 
The aim of this paper is to analyse the behaviour of ZnO 
nanocrystals (ZnO NCs), not embedded in any composite 
matrix, for bone implants applications in-vitro. We have 
developed a novel microwave-assisted synthesis to obtain the 
ZnO NCs in a fast, highly-reproducible and efficient way. Such 
NCs, having 20 nm in diameter and a high degree of 
crystallinity, are also chemically functionalized with amine 
groups, in order to investigate in-vitro the effect of their 
surface chemistry and charge.  
Thus, the role of ZnO NCs concentration and functionalization 
is tested both in terms of biocompatibility related to pre-
osteoblasts cells, promotion of cell proliferation and 
differentiation, and also in terms of antimicrobial activity 
against Gram positive and negative bacteria, such as 
Escherichia coli and Staphylococcus aureus. The results show a 
promising behaviour of amine-functionalized ZnO NCs for bone 
tissue engineering, even at high concentrations, leading to 
promoted osteogenic behaviour and high antimicrobial 
activity. It is thus demonstrated that a fine control over the 
chemical and structural parameters in ZnO nanomaterials can 
open new horizons in the use of functionalized ZnO NCs as a 
highly biocompatible nanoantibiotic for bone tissue 
engineering. 
Results and discussion 
We developed for this work a novel wet-chemical synthetic 
approach to obtain tiny and homogeneous ZnO NCs. The used 
approach involves a fast, highly-reproducible and efficient 
microwave-assisted synthesis method,
26
 hydrolysing the zinc 
acetate dehydrate precursor in a polar solvent (methanol) in 
presence of potassium hydroxide. The microwave-assisted 
solvothermal synthesis shows various advantages with respect 
to conventional synthetic procedures. In fact, due to a rapid 
and homogeneous heating it is possible to guarantee very fast 
kinetic rates and short reaction times, low energy 
consumption and simultaneous nucleation of nanocrystals that 
lead to obtain a uniform and reproducible dimensional 
range.
27
 
Thanks to this process, highly-dispersed, round-shaped 
nanocrystals as an extremely-stable colloidal solution in 
ethanol and water were finally obtained. Part of them were 
also chemically modified by anchoring amino-propyl groups to 
the ZnO surface, as previously reported by some of us.
10, 28, 29
 
The produced nanomaterials were then characterized as 
described below. 
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Figure 1.  Structural and morphological characterization: XRD patterns for (a) ZnO and (b) ZnO-NH2 NCs; TEM 
micrographs of (c) ZnO and (d) ZnO-NH2 NCs. 
Morphological and structural characterization of the ZnO NCs 
X-Ray Diffraction (XRD) was performed in order to obtain 
information about phase identification, along with phase 
quantification, percentage of crystallinity, crystallite size and 
unit cell size. Figures 1a and 1b show the XRD patterns of 
pristine ZnO NCs and ZnO-NH2 NCs. The comparison of 
patterns with data bank (JCPDS 36-1451) has confirmed the 
crystalline structure of the particles. In particular, the peaks at 
31.9°, 34.4°, 36.4°, 47.6°, 56.7° are indexed to (100), (002), 
(101), (102) and (110) planes, respectively.  These correspond 
to the Miller indexes of hexagonal wurtzite structure of ZnO, 
according to the literature
30, 31
 and compared with the 
standard reference pattern of ZnO. It is also clear that the 
chemical functionalization has not altered the crystalline 
structure of ZnO. By using the Debye-Scherrer formula and 
considering the dominant peaks, it was possible to estimate 
the dimension of crystallites, resulting to be around 15 nm for 
both pristine and functionalized ZnO NCs.  
Transmission Electron Microscopy (TEM) studies confirmed 
these results and allowed to obtain additional information 
about the particle’s morphology and size (Figures 1c and 1d), 
showing similar polygonal shape, typical of ZnO NCs in both 
cases. The stability behaviour of ZnO NCs show highly 
monodispersed particles sizes for both pristine and amine-
functionalized ZnO NCs in both ethanol and water media, as 
reported by the Dynamic Light Scattering measurements in 
Figures S1 of the Supporting Information (S.I.). Fourier-
Transform Infrared (FTIR) spectra of both ZnO and ZnO–NH2 
NCs show some common features between the two different 
samples, but in the case of ZnO–NH2 NCs the presence of 
typical vibration modes associated to functional groups 
present in the 3-aminopropyltrimethoxysilane molecule 
(APTMS) confirms the successful functionalization of the ZnO 
surface (Figure S2 in the S.I.).  
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Figure 2. In-vitro biocompatibility assays: cytotoxicity by LDH released into the medium after 3 days of incubation with different 
concentrations of (a) ZnO and (c) ZnO-NH2 NCs. Proliferation results in terms of mitochondrial activity (MTT) after 3 days of 
incubation and with different concentrations of (b) ZnO and (d) ZnO-NH2 NCs (p < 0.05, significant differences compared to 
control are denoted by an asterisk (*)) 
 
Biocompatibility studies  
The biocompatible or cytotoxic behaviours of both pristine and 
functionalized ZnO NCs at different concentrations were 
monitored in living pre-osteoblast cells from mouse calvaria. 
Both lactate dehydrogenase (LDH) production and the 
mitochondrial activity (MTT) were recorded after 3 days of cell 
incubation with the nanocrystals with and without 
functionalization and at different concentrations, to give a 
complete picture of the cytotoxicity and the cell proliferation 
behaviour. LDH is an enzyme released by cells in case of cell 
membrane rupture, thus indicating a cytotoxic effect. 
Interestingly, the LDH tests reported in Figures 2a and 2c for 
both pristine and functionalized ZnO NCs, respectively, 
evidenced no cytotoxic effect in both cases up to the 
concentration of 50 µg/mL of NCs. Actually, no significant 
differences were registered in comparison with the control 
test. In contrast, the concentration of 100 µg/mL of both 
pristine ZnO NCs and ZnO-NH2 NCs exhibited a cytotoxic effect 
on pre-osteoblast cells, displaying a double quantity of LDH 
produced with respect to the control.  
The MTT proliferation test is based on the ability of 
mitochondrial enzymes to reduce the MTT molecule to 
formazan. This measurement is commonly related with the cell 
viability and cell proliferation as previously reported in the 
literature.
32 
According to Figures 2b and 2d, both pristine and 
functionalized ZnO NCs showed an adequate cell proliferation 
up to a certain concentration: in general, a decrease of 
mitochondrial activity occurred by increasing the 
concentration of NCs with respect to the control without 
nanocrystals. The proliferation ranges from 90% to 70% up to 
the concentration of 25 µg/mL (compared to control), then a 
slight decrease occurs for 50 µg/mL (≈60%) both for pristine 
and functionalized NCs. Regarding the highest concentration of 
100 µg/mL, there is a significant reduction of the proliferation 
down to 27% for ZnO NCs and 43% for ZnO-NH2 NCs compared 
to the control. These results are in line with the LDH test. 
Therefore, both LDH and MTT assays has highlighted the great 
biocompatibility of ZnO and ZnO-NH2 up to the concentration 
of 50 µg/mL. On the other side, the concentration of 100 
µg/mL has shown a cytotoxic activity and inhibited the cell 
proliferation. This cytotoxic effect is generally reported in the 
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literature
10,
 
26
 as an intracellular release of cytotoxic Zn
2+
 
cations due to ZnO dissolution, or as a consequence of an 
oxidative stress by Reactive Oxygen Species, due to the ZnO 
present intracellularly.
33
 
 
Figure 3. Proliferation results in terms of MTT of MC3T3-E1 (at 
70% of confluence) and incubated for 1 day with different 
concentrations of (a) ZnO and (b) ZnO-NH2 NCs (p < 0.05, 
significant differences compared to control denoted by an 
asterisk (*)) 
In order to have further information on biocompatibility 
behaviour another assay was performed. The cells were 
cultured up to the 70% of confluence and then treated with 
the nanocrystals (at different concentrations and with or 
without functionalization). This procedure was necessary to 
simulate the interaction between a pre-formed bone tissue 
and antibacterial agents, in order to analyse how they may 
affect the viability of the tissue. In this case, the proliferation 
via MTT was measured after 24 h of incubation (Figure 3) and 
the cell morphology was studied under fluorescent microscope 
after 4 days of incubation (Figure 4). The values of MTT tests 
are of the same order of the control up to a concentration of 
50 µg/mL for pristine ZnO NCs. Actually, the mitochondrial 
activity is around 100% or higher compared to the control, 
with a peak of mitochondrial activity for the concentration of 
25 µg/mL, where the proliferation is increased up to 130%. 
Unfortunately, a significant decrease occurs in correspondence 
of the highest concentration (100 µg/mL), where 
mitochondrial activity drops down to 41%. These results are 
indeed comparable to what reported in Figure 2, showing 
again a concentration-dependence biocompatibility of the ZnO 
NCs. 
The results about ZnO-NH2 are similar with just few 
differences. The best proliferation value is obtained for the 
concentration of 25 µg/mL, but the peak is less pronounced. 
Interestingly, the concentration of 100 µg/mL does not show 
significant differences and the mitochondrial activity is still 
close to control. This result highlights the first difference 
between pristine and functionalized ZnO NCs. 
Confocal microscope images give further information and 
permit to investigate the cell morphology after ZnO NCs 
incubation. Actin was stained with Atto565-conjugated 
phalloidin (red) and nuclei stained with DAPI (blue). Figure 4 
shows the typical well-spread morphology of osteoblasts after 
incubation with ZnO NCs at 25 µg/mL. In addition, further 
images at the other concentrations are reported Figures S3 
and S4 in the S.I. Note that there is a slight increase of the 
number of the cell after incubation with the nanoparticules at 
25 µg/mL, which is confirmed by an increase in the cellular 
thickness from 73±10 m for the control to 123 ±15 m in 
presence of ZnO NCs. On the contrary, at higher concentration 
of pristine ZnO NCs (100 µg/mL), the cells exhibit a spherical 
morphology, non-defined actin filaments and reduced 
confluence, meaning a clear cytotoxic effect at this 
concentration. These results have confirmed the previous 
ones, evidencing a good biocompatibility of ZnO NCs up to 50 
µg/mL.
7
 
Regarding the functionalized ZnO-NH2 NCs, this cytotoxic 
effect is less noticeable, because the cells in contact with 100 
µg/mL show a well-spread morphology, still fluorescent actin 
filaments, but the grade of confluence is sensibly inferior 
compared to the control cells. ZnO-NH2 is again confirmed to 
be more biocompatible, especially for the highest sample 
concentration of 100 µg/mL in these experimental conditions. 
 
Differentiation assay: ALP 
Differentiation is a process by which unspecialized cells, pre-
osteoblasts, become specialized cells with the function to 
restore the bone. For this purpose, the activity of ALP (alkaline 
phosphatase), a marker enzyme for determining osteoblasts 
phenotype was monitored. In particular, the ALP activity of 
both kinds of ZnO NCs was determined after 10 days of 
incubation in pre-osteoblast cells. In Figure 5a it is possible to 
observe a progressive decrease of ALP activity by increasing 
the concentration of ZnO NCs, and even in this case the lowest 
value is for 100 µg/mL. Regarding the total protein content 
(Figure S5 top in the S.I.), the trend is very similar to the ALP 
activity. No significant differences are observed up to a 
concentration of 10 µg/mL, while there is a drop from 25 
µg/mL to higher concentration values. On the other side, the 
ZnO-NH2 NCs have shown a different behaviour. As it can be 
observed in Figure 5b, there are no significant differences 
compared to the control for the ALP activity, evidencing there 
is no apparent inhibition at the lower concentrations of 
nanoparticles (below 100 g/mL). At the highest concentration 
of 100 µg/mL, around 20% decrease of the ALP activity is 
obtained. A similar trend is observed for the total protein 
content in Figure S5 bottom of the S.I.  
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Figure 4. Confocal Microscopy images of pre-osteoblasts cultured up to 70% of confluence after incubation for 4 days with ZnO 
and ZnO-NH2 NCs at different concentrations. All confocal images have been obtained n the same conditions and are the Z projection of 
different images taken at different depths.
The cell morphology in bright field at optical microscope was 
also recorded at every concentration, both for the pristine and 
functionalized incubated NCs (see Figures S6 and S7 in the S.I.). 
MC3T3-E1 cells exhibit a well spread morphology, with a high 
degree of confluence, up to the concentration of 50 µg/mL for 
pristine ZnO NCs. As observed above, the cells treated with 
100 µg/mL of ZnO NCs present a spherical morphology, 
indicating cell sufferance and death, with a minor grade of 
confluence.  
Regarding the cells treated with ZnO-NH2 NCs for ten days at 
different concentrations, in all cases a well-spread morphology 
of MC3T3-E1 cells is observed, including the highest 
concentration of 100 µg/mL for ZnO-NH2 NPs. We can observe 
a slightly lower confluence for the most concentrated sample 
with respect to the other ones. However, these optical 
microscope images have confirmed the results of ALP activity 
and total protein content, showing the prominent 
biocompatible and osteoinductive role, even at high 
concentrations, of the ZnO-NH2 NCs. 
Antimicrobial activity 
The antimicrobial activity of different NCs was determined 
against Gram positive (S. aureus) and Gram negative (E. coli) 
bacteria in planktonic stage, after 24h of incubation at 
different concentration. Figure 6 summarizes these results in 
terms of logarithmic scale of CFU quantification. The obtained 
results show a remarkable antimicrobial effect in the 
antimicrobial activity in both pristine ZnO and functionalized 
ZnO-NH2 NCs against two bacteria for all bacteria. However, 
there is notable differences between both strains. Regarding 
the antimicrobial activity against E. coli, it is very interesting to 
notice that The results highlight particularly that there is no 
effect of NCs concentration, each one showing a 100% 
reduction of bacteria viability. The same behaviour was 
observed both for pristine and functionalized nanocrystals. On 
the other side, the activity against S. aureus was slightly 
different.  
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Figure 5. Differentiation assays in term of ALP after 10 days of 
incubation with (a) ZnO and (b) ZnO-NH2 NCs at different 
concentrations. (p < 0.05, significant differences compared to 
control denoted by an asterisk (*)) 
The peak of antimicrobial activity is obtained for the 
concentration of 25 μg/mL for both ZnO and ZnO-NH2 NCs, 
showing a reduction in viability around 99.98 and 99.99% 
(less than 100 CFU/mL), respectively. In contrast, the 
antimicrobial activity is reduced at higher concentration, in 
particular for the concentration of 50 μg/mL of ZnO-NH2 
NCs, resulting in only 99.85% of bacteria inactivation (in 
this case the concentration is higher of 10
2
 CFU/mL, which 
could considered not effective. This performance can be 
explained by the aggregation of nanocrystals when 
dispersed in PBS, as previously observed by some of us.
31
 In 
fact, by increasing the concentration, there is a greater 
probability to form huge aggregates, which means a lower 
surface area to volume ratio, and thus a reduced contact 
with the S. aureus population. This behaviour was not 
detected with E. coli probably because of the different 
shape and resistance. In fact, E. coli exhibits an elongated 
shape while S. aureus a round shape, thus aggregated NCs 
have a major probability to get in contact with E. coli. In 
addition, S. aureus is a more resistant and pathogenic 
bacteria compared to E. coli. For further information, Table 
S1 summarizes the reduction in bacteria viability. 
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Figure 6. Logarithmic scale of CFU per mL of E. coli and S. aureus in planktonic stage incubated for 24 h in the presence of 
different concentrations of ZnO and ZnO-NH2 NCs. (p < 0.05, significant differences compared to control denoted by an asterisk 
(*) in absolute value).  
 
Experimental 
ZnO synthesis and functionalization 
ZnO NCs were synthesized through a novel microwave-assisted 
synthesis approach by using as precursors zinc acetate di-
hydrate (0.1 M) and potassium hydroxide (0.2 M) (both from 
Sigma Aldrich) dispersed in methanol as solvent. The solution 
containing the zinc precursor was prepared and stirred directly 
in the reactor vessel. In order to initiate the zinc oxide 
nucleation, 0.48 µl of double-distilled water were added and 
then the KOH solution was mixed together in the reactor 
vessel. The resulting solution was put into microwave oven for 
30 minutes under control of pressure at temperature of 60 °C. 
After this time, the colloidal solution was collected and 
centrifuged for 10 minutes at 5000 rpm (3500 rcf), in order to 
separate the methanol and reaction residuals from the newly-
formed ZnO NCs. The surfactant was then removed and the 
precipitate was dispersed and washed in 15 mL of ethanol for 
two times. The as-obtained ZnO NCs pellet was suspended in 
fresh ethanol to give the final colloidal suspension. 
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The functionalization step of ZnO NCs with amino groups (NH2) 
was obtained combining nanocrystals with 3-
aminopropyltrimethoxysilane, (APTMS, 97%, Sigma) as already 
reported in [10]. More in details, 100 mg (1.23 mmol) of ZnO 
NCs, dispersed in ethanol, were heated to 80 °C in a 100 mL 
round glass flask under continuous stirring and nitrogen gas 
flow. 15 minutes later, 21.4 μL of APTMS (0.123 mmol, 22.05 
mg, corresponding to 10 mol% of total ZnO amount) was 
added to the solution. The obtained mixture was refluxed 
under a nitrogen gas flow for 6 h and successively washed two 
times by separating the NCs under centrifugation (10 min, 
10,000 rpm) to remove the unbound APTMS molecules. 
Characterization 
The ZnO NCs obtained from microwave-assisted synthesis 
were characterized by comparing data from different batches 
in order to confirm the synthesis’ repeatability. In particular, 
the samples were analyzed by XRD (X-Ray Diffraction) in order 
to investigate the crystalline structure. A Panalytical X’Pert 
diffractometer in configuration 0-2θ Bragg-Brentano was 
employed. This instrument uses a source of radiation Cu-Kα 
(λ=1.54 Å, 40 kV e 30 mA). The samples were prepared by 
depositing the colloidal solution drop by drop on a silicon 
wafer, in order to have a sufficiently thick layer of 
nanocrystals. The XRD analysis was carried out with step size 
of 0.02° (2θ), 2θ range of 20°–70° and with an acquisition time 
of 100 s. 
Transmission Electron Microscopy (TEM) characterization was 
also used to assess the morphology, size, shape and 
crystallinity of the nanocrystals. The samples were diluted in 
ultra-pure ethanol (99 %) up to a concentration of 200 μg/mL 
and then one drop was deposited on a copper grid with carbon 
mesh for HR-TEM analysis. The measurements were 
performed with JEM 2100HT (JEOL) multipurpose analytical 
HR-TEM, with an accelerating voltage of 200 kV and point 
resolution of 0.25 nm. HR-TEM images were acquired using a 
charge coupled device (CCD) camera. 
Cell culture conditions 
MC3T3-E1, pre-osteoblasts cells from mouse calvaria were 
used. Cells were grown in complete Dulbecco’s Modified 
Eagle’s Medium (α-DMEM, Sigma Chemical Company, St. 
Louis, MO, USA) supplemented with 2 mM L-glutamine 
(BioWhittaker), 100 μg·mL
-1
 penicillin (BioWhittaker), 100 
g·mL
-1
 streptomycin (BioWhittaker) and fetal bovine serum 
(FBS, Gibco) at 10% at 37 °C under atmosphere conditions of 
95% humidity and 5% CO2. Medium was changed every day 
until confluence reached ≈ 90% in a P75 flask. Then cultures 
were trypsinized with a solution of 0.05% (w/v) trypsin and 
0.02% (w/v) EDTA in sterile phosphate buffered saline (Sigma 
Aldrich) and counted with a Neubauer Hemocytometer. Cells 
were then centrifuged at 310 g for 10 min and suspended in 
fresh medium at a density of 2·104 cells/mL 
In cellular assays the behavior of both ZnO pristine and ZnO-
NH2 NCs was studied at the following concentrations: 5 µg/mL, 
10 µg/mL, 25 µg/mL, 50 µg/mL, 100 µg/mL. The desired 
amount of NCs was taken away from the stock solutions in 
ethanol, centrifuged to pellet the NCs and discard the ethanol, 
and then the NCs were dispersed in the final volume of cell 
culture medium. ZnO-free suspensions were used as control. In 
addition, two different experiments were performed. In the 
first one, cells and ZnO nanostructure were put in contact at 
the same time, to analyze the situation when stem cells and 
antimicrobial agents arrive simultaneously. In the second 
assay, cells were cultured up to the 70% of confluence, and 
then the nanocrystals were added. This procedure simulates 
the interaction between a pre-formed bone tissue and 
antibacterial agents, in order to analyse how they may affect 
the viability of the tissue. 
Citotoxicity test – LDH  
LDH activity was determined in the culture medium in contact 
with nanocrystals after 3 days of incubation. Activity of LDH 
released by the MC3T3- E1 cells is directly related to the 
rupture of the plasmatic membrane (cell death) that, when 
broken, releases all organelles and enzymes present in the 
cytoplasm. For this purpose, 0.750 mL of cell suspensions with 
a concentration of 1.33 x 10 4 cells/mL and 0.250 mL of NCs 
suspensions with the desired concentration were added in 
each plate. After adding NCs in the cells suspensions, the well 
plates were left in incubation under CO2 (5%) atmosphere at 
37 ℃ for 3 days. Measurements were performed by using a 
commercial kit (Spinreact) having an absorbance at 340 nm 
with a UV–Visible spectrophotometer. Two replicated were 
done for each concentration. 
Mitochondrial activity – MTT  
For evaluating cell mitochondrial activity of living cells on the 
different plates as well as its surroundings after 1 and 3 days of 
incubation, the MTT method was employed. This method is 
based in the reduction of 3-(4,5-dimethylazol-2-yl)-2,5-
diphenyltetrazolium (yellow) to blue formazan. This 
measurement was used in terms of cell proliferation. For this 
purpose, 0.750 mL of MC3T3-E1 cells in a concentration of 104 
cells/mL in complete medium were cultured in 24-well plates 
in presence of 0.250 ml of ZnO or ZnO-NH2 NCs suspension at 
different concentrations and incubated in 5% CO2 atmosphere 
at 37℃ for 3 days. This test was replicated for pre-formed 
bone tissue where NCs were incubated for 1 day with cells at 
70% of confluence. After this time, the culture medium was 
substituted with 1 mL of α-MEM and 125 μL of MTT solution (5 
mg/mL in PBS 1x) was added. Samples were incubated for 4 h 
at 37 ℃ and 5% CO2 in dark conditions. Then, medium was 
removed and 500 μl of HCl-isopropanol solution 0.4 M was 
added. At the end, the absorbance at 570 nm was measured. 
Two replicates were done for each concentration. 
Cell morphology studies  
The morphology of pre-osteoblast cells MC3T3-E1 was studied 
in AMG EVOS fl LED Fluorescent Microscope. For this purpose, 
cells were cultured up to 70% of confluence, and then the 
medium was taken off. Afterwards 0.750 mL of complete α-
MEM and 0.250 mL of NCs suspensions with the desired 
concentration were added in each plate. Samples were 
incubated for 4 days. After this time, adherent cells were fixed 
ARTICLE Journal Name 
10 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
with Paraformaldehyde (4% in PBS) for 30 minutes. Then Atto 
565-conjugated phalloidin and DAPI were added in each plate 
to stain respectively cell actin in red and cell nuclei in blue.  
Differentiation assay: Alkaline phosphatase activity – ALP 
For evaluating the differentiation of MC3T3-E1, ALP 
measurements were employed. Alkaline phosphatase is an 
enzyme present in most of the organisms, with high quantities 
in bone, liver, placenta, intestine and kidney. ALP of the cells 
growing in contact with ZnO nanostructures was utilized as 
marker of cellular differentiation in the evaluation of the 
phenotype expression of osteoblasts. 
For this purpose, MTC3T3-E1 pre-osteoblastic cells (104 
cells/mL) were cultured directly in a 24-well plate and 
incubated for 10 days in contact with ZnO and ZnO-NH2 under 
standard culture conditions (37 ℃, 5% CO2) using α-MEM 
completed medium supplemented with b-glycerolphosphate 
(50 mg/mL) and L-ascorbic acid (10 mM). In particular, 0.750 
mL of cells suspensions with a concentration of 1.33 x 10 
4
 
cells/mL and 0.250 mL of NCs suspensions with the desired 
concentration were added in each plate. Two replicates were 
done for each samples in two independent assays (n=4). 
After incubation for 10 days, the medium was taken off and 
every well plate was washed twice with PBS (pH 7.4). 
Successively, samples were frozen and before the 
measurement they were frozen and unfrozen for 3 times in 
order to break the cell membrane and release ALP. ALP was 
measured employing the Spinreact kit. 
CFU counting method 
To examine the bactericidal effect of ZnO NCs on bacteria, in 
planktonic stage, direct incubation with bacteria soalution in 
PBS was carried out. Both E. coli 25922 and S. aureus 
ATCC29213 (methicillin-sensitive) have been used. In this case, 
the concentrations of 5 µg/mL, 10 µg/mL, 25 µg/mL, 50 µg/mL, 
100 µg/mL were used in order to determine their effectivity. 
For this purposes 0.750 mL of bacteria suspensions in PBS with 
a concentration of 1.33 x 10
6
 bacteria/mL and 0.250 mL of NCs 
suspensions with the desired concentration were added in 
each well of a 24-well plate. Then, NCs and bacteria 
suspensions were incubated for 24 h under orbital stirring at 
37 ℃. Two different experiments were performed for 
triplicated. The quantification of lived bacteria was determined 
by CFUs in agar. In order to be more accurate original solution 
and different dilutions (1/10, 1/100 and 1/1000 dilutions) were 
done. Thus, 20 L of such solutions was seeded onto trypsin 
soy agar (TSA), incubated at 37 ºC overnight and subsequently 
the number of CFUs was counted. Positive controls containing 
bacteria was also performed and the experiments were 
performed in triplicate.  
Statistical analysis 
Data are expressed as average/mean ± standard deviation in 
two experiments. The software Statistical Package for the 
Social Sciences (SPSS) version 11.5 was used to perform 
statistical analysis. the variance analysis (ANOVA) was utilized 
for Statistical comparatives. Scheff proof was used for the post 
hoc evaluation of the differences among groups. In all 
statistical evaluations, p < 0.05 was considered as statistically 
significant. 
  
Conclusions 
In this work, uniform and highly crystalline ZnO nanoparticles 
were synthesized by an innovative microwave-assisted 
solvothermal synthesis to obtain nanocrystals of 20 nm in 
diameter. The results have highlighted that ZnO NCs show a 
great biocompatibility, towards pre-osteoblast cells and a 
promising antimicrobial activity against E. coli and S. aureus. 
Moreover, the biocompatibility and antibacterial assays 
performed on the functionalized ZnO-NH2 NCs also 
demonstrated that a fine control over the ZnO chemical 
surface by amine-functionalization further improve both 
biocompatibility in terms of cell differentiation and 
proliferation and their antimicrobial capability. These findings 
open new horizons in the use of ZnO NCs as a highly 
biocompatible nanoantibiotic for bone tissue engineering. 
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